Chiesi hands back gene therapy to uniQure

12:15 EDT 1 Aug 2017 | BioPharmaDive

On the heels of Glybera's commercial flop, uniQure loses its development partner for a gene therapy currently in mid-stage testing for hemophilia B.

Original Article: Chiesi hands back gene therapy to uniQure


More From BioPortfolio on "Chiesi hands back gene therapy to uniQure"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...